Underutilization of β-adrenoceptor antagonists post-myocardial infarction

American Journal of Cardiovascular Drugs

Volumn 5, Issue 1, 2005, Pages 23-29

  Gutierrez, Michael E ^a   Labovitz, Arthur J ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESMOLOL; HYPOCHOLESTEROLEMIC AGENT; LABETALOL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NADOLOL; PINDOLOL; PROPRANOLOL; RAMIPRIL; TIMOLOL;

BRONCHOSPASM; CARDIOSELECTIVITY; CAUSE OF DEATH; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG USE; GERIATRIC PATIENT; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; INTRINSIC SYMPATHOMIMETIC ACTIVITY; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; CLINICAL TRIALS; CORONARY DISEASE; DRUG UTILIZATION; HUMANS; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 12744253852     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200505010-00004     Document Type: Review

References (47)

1. Anderson RN. Center for Disease Control, Maryland. Deaths: leading causes for 2000. National Vital Statistics Reports 2002 Sep 16; 50 (16): 9 [online]. Available from URL: http://www.cdc.gov/nchs/data/nvsr/nvsr50/nvsr50_16.pdf [Accessed 2004 Dec 16]
2. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999 Dec 9; 341 (24): 1789-94
3. Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery: Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996 Dec 5; 335 (23): 1713-20
4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: the US Carvedilol Heart Failure Study Group. N Engl J Med 1966 May 23; 334 (21): 1349-55
5. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisprolol Study II (CIBIS-II): a randomized trial. Lancet 1999 Jan 2; 353 (9146): 9-13
6. The MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in congestive Heart Failure (MERIT-HF). Lancet 1999 Jun 12; 353 (9169): 2001-7
7. Hampton JR. Beta blockade and the secondary prevention of myocardial infarction. Acta Med Scand Suppl 1981; 651: 219-26
8. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982 Mar 26; 247 (12): 1707-14
9. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981 Apr 2; 304 (14): 801-7
10. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981 Oct 17; II (8251): 823-7
11. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986 Jul 12; II (8498): 57-66
12. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001 May 5; 357 (9266): 1385-90
13. Boissel JP, Leizorovicz A, Picolet H, et al. Efficacy of acebutolol after acute myocardial infarction (the APSI trial): the APSI investigators. Am J Cardiol 1990 Sep 25; 66 (9): 24C-31C
14. Yusef S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985 Mar-Apr; 27 (5): 335-71
15. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction: results of the survival and ventricular enlargement trial: the SAVE investigators. Circulation 1994 Oct; 90 (4): 1731-8
16. Spargias KS, Hall AS, Greenwood DC, et al. Beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Heart 1999; 81: 25-32
17. Janosi A, Ghali JK, Herlitz J, et al. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. Am Heart J 2003 Oct; 146 (4): 721-8
18. Olsson G, Ablad B, Ryden L. Long-term cardiovascular effects of metoprolol therapy: a review article. J Clin Pharmacol 1990 Feb; 30 (2 Suppl.): S118-23
19. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003 Dec; 100 (3): 215-34
20. Book WM. Carvedilol: a nonselective beta blocking agent with antioxidant properties [published erratum appears in Congest Heart Fail 2002 Jul-Aug; 8 (4): 240]. Congest Heart Fail 2002 May-Jun; 8 (3): 173-7, 190
21. Anzai T, Yoshikawa T, Takahashi T, et al. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 2003; 99 (1): 47-53
22. Feng DL, Tofler GH. Diurnal physiologic processes and circadian variation of acute myocardial infarction. J Cardiovasc Risk 1995 Dec; 2 (6): 494-8
23. Muller JE. Circadian variation and triggering of acute coronary events. Am Heart J 1999 Apr; 137 (4 Pt 2): S1-8
24. Vaishnav S, Stevenson R, Marchant B, et al. Relationship between heart rate variability early after acute myocardial infarction and long-term mortality. Am J Cardiol 1994 Apr 1; 73 (9): 653-7
25. Fei L, Copie X, Malik M, et al. Short- and long-term assessment of heart rate variability for risk stratification after acute myocardial infarction. Am J Cardiol 1996 Apr 1; 77 (9): 681-4
26. Lampert R, Ickovics JR, Viscoli CJ, et al. Effects of propranolol on recovery of heart rate variability following acute myocardial infarction and relation to outcome in the Beta-Blocker Heart Attack Trial. Am J Cardiol 2003 Jan 15; 91 (2): 137-42
27. Sandrone G, Mortara A, Torzillo D, et al. Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. Am J Cardiol 1994 Aug 15; 74 (4): 340-5
28. American Medical Association, Quality Care Alert. Beta-blocker prophylaxis after acute myocardial infarction [online]. Available from URL: http://www.ncqa.org/somc2001/BETA_BL/SOMC_2001_BBH.html [Accessed 2004 Dec 1]
29. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Committee on the Management of Patients With Unstable Angina. Circulation 2000; 102: 1193-209
30. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Committee on Management of Acute Myocardial Infarction. J Am Coll Cardiol 1999 Sep; 34 (3): 890-911
31. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002 Oct 22; 106 (17): 2194-9
32. Gottlieb SS, McCarter RJ. Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after acute myocardial infarction. Am J Cardiol 2001 Apr 1; 87 (7): 823-6
33. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998 Aug 20; 339 (8): 489-97
34. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998 Aug 19; 280 (7): 623-9
35. Sial SH, Malone M, Freeman JL, et al. Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. J Gen Intern Med 1994 Nov; 9 (11): 599-655
36. Brand DA, Newcomer LN, Freiburger A, et al. Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995 Nov 15; 26 (6): 1432-6
37. Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995 May; 25 (6): 1327-32
38. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation 1994 Oct; 90 (4): 2103-14
39. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for medicare patients with acute myocardial infarction: results from the cooperative cardiovascular project. JAMA 1998 May 6; 279 (17): 1351-7
40. Deedwania PC. Beta-blockers and adverse effects: dispelling the myths. Patient Care 2002 Jul; 9: 28-42
41. Tafreshi MJ, Weinacker AB. Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy 1999 Aug; 19 (8): 974-8
42. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 1997 Jun 15; 126 (12): 955-9
43. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol. European Trial (COMET): a randomised controlled trial. The COMET Investigators. Lancet 2003; 362: 7-13
44. Mitchell RG, Stoddard MF, Ben-Yehuda O, et al. Esmolol in acute ischemic syndromes. Am Heart J 2002 Nov; 144 (5): E9-12
45. Hjalmarson A. Effects of beta blockade on sudden death during acute myocardial infarction and the postinfarction period. Am J Cardiol 1997 Nov 13; 80 (9B): 35J-9J
46. Askenazi J, MacCosbe PE, Hoff J, et al. Hemodynamic effects of esmolol, an ultra-short acting beta blocker. J Clin Pharmacol 1987 Aug; 27 (8): 567-73
47. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988 Jan; 9 (1): 8-16